Time of erythema onset after application of methyl nicotinate ointments as response parameter: Influence of penetration kinetics and enhancing agents

Skin Pharmacology and Physiology

Volumn 19, Issue 6, 2006, Pages 303-310

  Remane, Y ^a   Leopold, C S ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Bioequivalence; Diethylene glycol monoethyl ether; Dimethyl sulfoxide; Glyceride; Methyl nicotinate; Penetration enhancement; Penetration kinetics; Percutaneous penetration

Indexed keywords

ACYLGLYCEROL; DIETHYLENE GLYCOL MONOETHYL ETHER; DIMETHYL SULFOXIDE; GLYCEROTRIHEXANOATE; HEXANOIC ACID DERIVATIVE; MACROGOL 6 GLYCEROCAPRYLOCAPRATE; MACROGOL DERIVATIVE; MEDIUM CHAIN TRIACYLGLYCEROL; MINERAL OIL; NICOTINIC ACID METHYL ESTER; OCTANOIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHEMICAL REACTION KINETICS; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; ERYTHEMA; FEMALE; FOREARM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RESPONSE TIME; SKIN PENETRATION; STANDARD; THERMODYNAMICS;

ADULT; ALGORITHMS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; ERYTHEMA; FEMALE; HUMANS; LIPID BILAYERS; MALE; MIDDLE AGED; NICOTINIC ACIDS; OINTMENTS; SKIN ABSORPTION; THERMODYNAMICS;

EID: 33751307221     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095250     Document Type: Article

References (39)

1. Leopold CS, Maibach HI: Percutaneous penetration of local anesthetic bases: pharmacodynamic measurements. J Invest Dermatol 1999;113:304-307.
2. Demana PH, Smith EW, Walker BR, Haigh JM, Kanfer I: Evaluation of the proposed FDA pilot dose-response methodology for topical corticosteroid bioequivalence testing. Pharm Res 1997;14:303-307.
3. Crank J: Mathematics of Diffusion. London, Oxford University Press, 1956.
4. Lafforgue C, Eynard I, Falson F, Watkinson AC, Hadgraft J: Percutaneous absorption of methyl nicotinate. Int J Pharm 1995;84:640-642.
5. Guy RH, Wester RC, Tur E, Maibach HI: Non-invasive assessments of the percutaneous absorption of methyl nicotinate in humans. J Pharm Sci 1983;72:1077-1079.
6. Walters KA, Walker M, Olejnik O: Hydration and surfactant effects on methyl nicotinate penetration through hairless mouse skin. J Pharm Pharmacol 1985;37S:76P.
7. Moghimi HR, Williams AC, Barry BW: A lamellar matrix model for stratum corneum intercellular lipids. II. Effect of geometry of the stratum corneum on permeation of model drugs 5-fluorouracil and oestradiol. Int J Pharm 1996;131:117-129.
8. Chan SY, Po ALW: Quantitative assessment of non-steroidal anti-inflammatory topical products in nicotinate-induced erythema using tristimulus colour analysis. Int J Pharm 1992;83:73-86.
9. Reinberg AE, Soudant E, Koulbanis C, Bazin R, Nicolai A, Mechkouri M, Touitou E: Circadian dosing time dependency in the forearm skin penetration of methyl and hexyl nicotinate. Life Sci 1995;57:1507-1513.
10. Benson HAE, McElnay JC, Harland R, Hadgraft J: Influence of ultrasound on the percutaneous absorption of nicotinate esters. Pharm Res 1991;8:204-209.
11. Issachar N, Gall Y, Borrel MT, Poelmann MC: Correlation between percutaneous penetration of methyl nicotinate and sensitive skin, using laser Doppler imaging. Contact Dermatitis 1998;39:182-186.
12. Elsner P, Maibach HI: Cutaneous responses to methyl nicotinate in human forearm and vulvar skin. J Derm Sci 1991;2:341-345.
13. Guy RH, Tur E, Bjerke S, Maibach HI: Are there age and racial differences to methyl nicotinate-induced vasodilatation in human skin? J Am Dermatol 1985;12:1001-1006.
14. Ashton P, Walters KA, Brain KR, Hadgraft J: Surfactant effects in percutaneous absorption. I. Effects on the transdermal flux of methyl nicotinate. Int J Pharm 1992;87:261-264.
15. Williams AC, Barry BW: Skin absorption enhancers. Crit Rev Ther Drug Carrier Syst 1992;9:305-353.
16. Hadgraft J: Modulation of the barrier function of the skin. Skin Pharm Appl Skin Phys 2001;14:72-81.
17. Loth H: Vehicular influence on transdermal drug penetration. Int J Pharm 1991;68:1-10.
18. Tanojo H, Boelsma E, Junginger HE, Ponec M, Boddé HE: In vivo human skin permeability enhancement by oleic acid: a laser Doppler velocimetry study. J Control Release 1999;58:97-104.
19. Leopold CS, Lippold BC: Enhancing effects of lipophilic vehicles on skin penetration of methyl nicotinate in vivo. J Pharm Sci 1995;84:195-198.
20. Bach M, Lippold BC: Influence of penetration enhancers on the blanching intensity of beta-methasone 17-benzoate. Int J Pharm 1998;168:97-108.
21. Leopold CS: Quantification of depletion in solution-type topical preparations in vivo. J Cosmet Sci 1998;49:165-174.
22. Ryatt KS, Stevenson JM, Maibach HI, Guy RH: Pharmacodynamic measurement of percutaneous penetration enhancement in vivo. J Pharm Sci 1986;75:374-377.
23. Taylor LJ, Lee RS, Long M, Rawlings AV, Tubek J, Whitehead L, Moss GP: Effect of occlusion on the percutaneous penetration of linoleic acid and glycerol. Int J Pharm 2002;249:157-164.
24. Fluhr JW, Lazzerini S, Distante F, Gloor M, Berardesca E: Effects of prolonged occlusion on stratum corneum barrier function and water holding capacity. Skin Pharmacol Appl Skin Physiol 1999;12:193-198.
25. Leopold CS, Lippold BC: A new application chamber for skin penetration studies in vivo with liquid preparations. Pharm Res 1992;9:1215-1218.
26. Smith EW, Haigh JM, Surber C: Quantification of corticosteroid-induced skin vasoconstriction: visual ranking, chromameter measurement or digital imaging analysis. Dermatology 2002;205:3-10.
27. Waring MJ, Monger L, Hollingsbee DA, Martin GP, Marriott C: Assessment of corticosteroid-induced skin blanching: evaluation of the Minolta Chromameter CR 200. Int J Pharm 1993;94:211-222.
28. Lippold BC, Reimann H: Wirkungsbeeinflussung bei Lösungssalben durch Vehikel am Beispiel von Methylnicotinat. II. Beziehung zwischen relativer thermodynamischer Aktivität, Bioverfügbarkeit: Penetrationsbeschleunigung und Entleerungseffekt. Acta Pharm Tech 1989;35:136-142.
29. Hadgraft J: Skin deep. Eur J Pharm Biopharm 2004;58:291-299.
30. Curdy C, Kalia YN, Guy RH: Post-iontophoresis recovery of human skin impedance in vivo. Eur J Pharm Biopharm 2002;53:15-21.
31. Edwards DA, Prausnitz MR, Langer R, Weaver JC: Analysis of enhanced transdermal transport by skin electroporation. J Control Release 1995;34:211-221.
32. Fang JY, Hwang TL, Huang YB, Tsai YH: Transdermal iontophoresis of sodium nonivamide acetate. V. Combined effect of physical enhancement methods. Int J Pharm 2002;235:95-105.
33. Barry BW: Mode of action of penetration enhancers in human skin. J Control Release 1987;6:85-97.
34. Aungst BJ, Rogers NJ, Shefter E: Enhancement of naloxone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulphoxides and amides. Int J Pharm 1986;33:225-234.
35. Ganem-Quintanar A, Lafforgue C, Falson-Rieg F, Buri P: Evaluation of the transepidermal permeation of diethylene glycol monoethyl ether and skin water loss. Int J Pharm 1997;147:165-171.
36. Suhonen TM, Bouwstra JC, Urtti A: Chemical enhancement of percutaneous absorption in relation to stratum corneum structural alterations. J Control Release 1999;59:149-161.
37. Harrison JE, Watkinson AC, Green DM, Hadgraft J, Brain K: The relative effect of Azone® and Transcutol® on permeant diffusivity and solubility in human stratum corneum. Pharm Res 1996;13:542-546.
38. Panchagnula R, Ritschel WA: Development and evaluation of an intracutaneous depot formulation of corticosteroids using transcutol as a cosolvent: in-vitro, ex-vitro and in-vivo rat studies. J Pharm Pharmacol 1991;43:609-614.
39. Leopold CS, Lippold BC: An attempt to clarify the mechanism of the penetration enhancing effect of lipophilic vehicles with differential scanning calorimetry (DSC). J Pharm Pharmacol 1995;47:276-281.